banner

CXM - Cardium Therapeutics Inc.back to homepage

Cardium Therapeutics (CXM) LogoCardium Therapeutics Website
 

Get connected with Cardium Therapeutics.
 
 
Request More CXM Information
View all articles and comment in the CXM blog

About Cardium Therapeutics

Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium’s current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company’s in-house MedPodium Health Sciences healthy lifestyle product platform. The Company’s lead commercial product Excellagen™ topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. Cardium’s lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company’s biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

PRESENTATIONS

Cardium Investor Presentation May 2012

Cardium Investor Presentation May 2012


Cardium Generx Presentation

Cardium Generx Presentation


Cardium Excellagen Presentation

Cardium Excellagen Presentation


OUTLOOK FOR 2012

During 2012, Cardium plans to advance the commercialization of its new Excellagen wound care product through strategic partners in the U.S., as well as internationally; develop new product extensions based on Excellagen’s formulated collagen product platform for additional wound healing applications; advance forward with the ASPIRE Generx clinical study at leading medical centers in the Russian Federation for patients with advanced coronary disease; introduce additional product line extensions and broaden national distribution of the Company’s MedPodium healthy lifestyle product platform; and continue to identify and evaluate businesses, product opportunities and technologies for potential acquisition on favorable economic terms consistent with the Company’s long-term business strategy.


HISTORY OF CARDIUM THERAPEUTICS

  • October 2005 - Acquired a portfolio of biologic growth factors from the Schering AG Group for potential use in treating ischemic and other cardiovascular conditions, including Generx®, a product candidate being developed for patients with chronic myocardial ischemia
  • March 2006 - Acquired technologies and products of InnerCool Therapies, Inc., a medical technology company in the emerging field of therapeutic hypothermia or patient temperature modulation
  • August 2006 - Acquired Tissue Repair Company, a company focused on the development of therapeutics for the potential treatment of chronic wounds and other tissue injuries, including our Excellagen™ and Excellarate™ product candidates
  • July 2009 - Sold InnerCool Therapies to Royal Philips Electronics (NYSE: PHG)
  • November 2010 - Launched the MedPodium™ modern lifestyle product line, a portfolio of premium, science-based, easy to use nutraceuticals, metabolics and aesthetics designed to promote health and well-being.
  • January 2012 - Agreement for the sale and distribution of Excellagen™ in South Korea
  • January 2012 - Initiated the ASPIRE clinical study at leading medical centers in Russia for Cardium’s Generx® cardiovascular product candidate
  • March 2012 - Initiated U.S. market introduction of Excellagen™ product for diabetic foot ulcers and other dermal wounds


MANAGEMENT

  • Christopher J. Reinhard - Chairman of the Board, Chief Executive Officer, President and Treasurer
    Mr. Reinhard is a co-founder of Cardium and has served as a director and the Chief Executive Officer, President and Treasurer of Cardium since its inception in December 2003. Mr. Reinhard has also served as a director and the Chief Executive Officer and President of Tissue Repair Company, a wholly-owned subsidiary of Cardium since August 2006. He served as a director and the Chief Executive Officer and Treasurer of Cardium’s InnerCool Therapies subsidiary from its acquisition in March 2006 until its sale to Royal Philips Electronics in July 2009. For almost 15 years, Mr. Reinhard has focused on the commercial development of cardiovascular growth factor therapeutics. Before founding Cardium, he was a co-founder of Collateral Therapeutics, Inc., and served as a director (from 1995) and President (from 1999) of Collateral until its 2002 acquisition by the Schering Group, Germany (now part of Bayer HealthCare). He continued as Chief Executive of Collateral through December 2004. Mr. Reinhard played a major role in effecting Collateral’s initial public offering led by Bear Stearns & Co. in 1998, and the sale of Collateral to Schering. Mr. Reinhard also served as Executive Chairman of Artes Medical from 2004 to 2008. Previously, Mr. Reinhard was Vice President and Managing Director of the Henley Group, a publicly-traded diversified industrial and manufacturing group, and Vice President of various public and private companies created by the Henley Group through spin-out transactions, including Fisher Scientific Group, a leading international distributor of laboratory equipment and test apparatus for the scientific community, Instrumentation Laboratory and IMED Corporation, a medical device company. Mr. Reinhard received a B.S. in Finance and an M.B.A. from Babson College.
  • Tyler M. Dylan-Hyde, Ph.D., J.D. - Director, Chief Business Officer, General Counsel, Executive Vice President and Secretary
    Cardium VideoDr. Dylan-Hyde is a co-founder of Cardium and has served as a director and as the company’s General Counsel, Executive Vice President and Secretary since its inception in December 2003, and as its Chief Business Officer since May 2005. Since August 2006, Dr. Dylan-Hyde has also served as a director and Chief Business Officer, General Counsel, Executive Vice President and Secretary of Tissue Repair Company, a wholly-owned subsidiary of Cardium. He served as a director and Chief Business Officer of Cardium’s InnerCool Therapies subsidiary from its acquisition in March 2006 until its sale to Royal Philips Electronics in July 2009. Dr. Dylan-Hyde has focused on the development of biologics and devices for cardiovascular and ischemic diseases for more than a decade. He served as General Counsel and Vice President of Collateral Therapeutics, Inc. until its 2002 acquisition by the Schering Group, Germany (now part of Bayer HealthCare). Dr. Dylan-Hyde played a major role in developing Collateral’s intellectual property portfolio, in furthering its business development efforts and in advancing the company toward and through its acquisition by Schering, and continued as an executive officer and later consultant until 2005. Dr. Dylan-Hyde has advised both privately-held and publicly-traded companies that are developing, partnering or commercializing technology-based products. Before joining Collateral, Dr. Dylan-Hyde was a partner of the law firm of Morrison & Foerster LLP. In his law firm practice, he focused on the development, acquisition and enforcement of intellectual property rights, as well as related business and transactional issues. He also has worked with both researchers and business management in the biotech and pharmaceutical industries. Dr. Dylan-Hyde received a B.Sc. in Molecular Biology from McGill University, Montreal, Canada, a Ph.D. in Biology from the University of California, San Diego, where he performed research at the Center for Molecular Genetics, and a J.D. from the University of California, Berkeley.
  • Dennis M. Mulroy ,CPA - Chief Financial Officer
    Mr. Mulroy has been the Chief Financial Officer of Cardium since November 2005. He has also served as a director, Chief Financial Officer and Treasurer of Tissue Repair Company, a wholly-owned subsidiary of Cardium since August 2006. He served as a director and the Chief Financial Officer and Treasurer of Cardium’s InnerCool Therapies subsidiary from its acquisition in March 2006 until its sale to Royal Philips Electronics in July 2009. Mr. Mulroy was Chief Financial Officer of Molecular Imaging Corporation, a publicly-traded diagnostic services company (January 2004 – November 2005), SeraCare Life Sciences, Inc., a publicly-traded company (November 2001 – June 2003), and Bioceutix Inc. (January 2001 – November 2001). Mr. Mulroy was also employed with Ernst & Young in San Diego, California and is a Certified Public Accountant in the State of California. He received his degree in Business Administration from the University of San Diego.
  • Gabor M. Rubanyi, M.D., Ph.D. - Chief Scientific Officer
    Dr. Rubanyi has been the Chief Scientific Officer of Cardium since June 2006. From November 2005 until March 2006, he provided consulting services to Cardium. In March 2006, Dr. Rubanyi became an employee and a Scientific Advisor of Cardium. Before joining Cardium in March 2006, Dr. Rubanyi was Vice President of Gene Therapy at Berlex Biosciences (a subsidiary of Berlex Laboratories, the U.S. pharmaceutical affiliate of the Schering AG Group, Germany), and Adjunct Professor at the University of California, Davis. He initiated and played a leading role in the Angiogenic Gene Therapy for Coronary Artery Disease project at Schering/Berlex. Formerly, Dr. Rubanyi was Director of Vascular and Endothelial Research at Berlex (1992-1999), Director of the Institute of Pharmacology at Schering AG, Research Center, Berlin, Germany (1990-1992), Director of Pharmacology at Berlex Laboratories (1987-1990), and Associate Professor at the Mayo Clinic Medical School (1983-1987). Since 2006, Dr. Rubanyi has served as a director of Hybrid Systems, Ltd., a private, United Kingdom biotech company. Dr. Rubanyi is the author or co-author of 22 books and over 325 research articles, serves as an editorial board member to several biomedical journals and is the founder of the biomedical journal Endothelium. He also is a member of numerous American and international scientific societies. His pioneering work on the nature and characterization of endothelium-derived relaxing factors (nitric oxide) and contracting factors (endothelin) contributed substantially to the Company’s present knowledge about endothelial control of vascular function in health and disease, including angiogenesis.
  • Robert L. Engler, M.D. - Chief Medical Advisor
    Dr. Engler was co-founder of Collateral Therapeutics and served as a Director from 1995 to 2000 and as Vice President — Medical Director from 1995 through 1998. Currently, Dr. Engler is Professor of Medicine Emeritus at the University of California, San Diego (UCSD). He was Professor of Medicine at UCSD, Associate Chief of Staff for Research and Development at the Veterans’ Affairs Medical Center, and a faculty member of the Institute for Biomedical Engineering at UCSD. He served as director of Coronary Care at the VA Hospital and was a clinical cardiologist until 2001 when he retired from UCSD and the VA Hospital to continue his work in the development of innovative agents for cardiovascular therapy. From 1985 to 1997, Dr. Engler was a Scientific Advisor to Gensia. Dr. Engler is a director of Halozyme Therapeutics, a publicly-traded biotechnology company. He received a B.A. in Physics from the University of North Carolina and his medical degree from Georgetown University.
  • Mark McCutchen - Vice President, Business Development
    Mr. McCutchen is Vice President, Business Development of Cardium Therapeutics and was appointed Vice President, Business Development of Tissue Repair Company following Cardium’s acquisition of the company in August 2006. Prior to the acquisition, Mr. McCutchen served as Vice President and Chief Financial Officer of the Tissue Repair Company. Mr. McCutchen has over 15 years of financial and business management experience in the life sciences industry. Mr. McCutchen joined Selective Genetics (formerly Prizm Pharmaceuticals) in 1993 and has been Vice President and CFO since 1994. Heading up Selective Genetics’ financial activities he has overseen 7 rounds of venture and private financings totaling more than $60 million. He also managed the spinning out of non-core technology to form a new venture backed company as well as the merger forming Selective Genetics. He has been involved in multiple corporate partnering transactions with companies such as Chiron and Biomet. Prior to joining Selective Genetics, Mr. McCutchen held various finance positions, the most recent of which was with Viagene, Inc., one of the first gene therapy biotechnology companies acquired by Chiron Corporation. He started his finance career in the investment banking industry where he was engaged in equity and debt transactions for high technology and life science companies. Mr. McCutchen received his B.A. in psychology with pre-medical sciences from Wheaton College and M.B.A. from the University of Washington, with a concentration in finance.
  • Ted Williams - Vice President, Manufacturing and Technical Operations
    Mr. Williams has served as Vice President – Manufacturing and Technical Operations of Cardium Therapeutics since November 2005 and as Vice President – Manufacturing and Technical Operations of Cardium’s wholly-owned subsidiary, Tissue Repair Company since August 2006. He served as Vice President – Manufacturing and Technical Operations Cardium’s InnerCool Therapies subsidiary from its acquisition in March 2006 until its sale to Royal Philips Electronics in July 2009. Mr. Williams brings over 25 years of professional experience in FDA-regulated environments of biopharmaceutical Process Development, cGMP manufacturing, successful medical device development, Quality Control, Quality Assurance, Environmental Monitoring, microbiological controls and analytical methods development. Prior to joining Cardium, Mr. Williams was Senior Director of Quality Control at Favrille, Inc., a publicly-traded biotechnology company. From 2001 to 2004, he was Director of Research Operations, Process Technologies and Quality Systems at Collateral Therapeutics where he was involved in research and development efforts related to Generx and other product candidates. Mr. Williams was Senior Manager of Quality Systems at Advanced Tissue Sciences from 1998 to 2001, Manager of Quality Control at Chiron Technologies, Center for Gene Therapy from 1995 to 1998, and Supervisor of Quality Control at Viagene Inc. from 1992 to 1995. From 1978 to 1992, he was Chief Microbiologist and Supervisor of the Clinical Microbiology Department at Yuma Regional Medical Center. Mr. Williams earned his B.S. in microbiology from Weber State University, Ogden, Utah.
  • Lois A. Chandler, Ph.D. - Vice President, Biologics Development
    Dr. Chandler has served as Vice President, Biologics Development of Cardium since July 2010 and served as Senior Director, Product Development of Cardium’s wholly-owned subsidiary, Tissue Repair Company, from August 2006 to July 2010. Dr. Chandler has 17 years of professional experience in biopharmaceutical design and clinical development, Chemistry, Manufacturing and Controls, Quality Control and custom DNA vector design. Prior to joining Tissue Repair Company in January 2006, Dr. Chandler served as Associate Director, Vector Development for Selective Genetics Inc, a company that developed targeted viral and non-viral DNA therapeutics for dermal, cardiovascular, and orthopedic tissue repair. At Selective Genetics, Dr. Chandler oversaw the developmental Chemistry, Manufacturing and Control efforts related to Excellarate and Excellagen as well as other targeted gene therapy preclinical programs. She also served as Supervisor of the Molecular Biology, Analytical Development and Assay Development departments. Prior to Selective Genetics, Dr. Chandler was employed by Prizm Pharmaceuticals as a Senior Scientist, Molecular Biology designing novel recombinant mitotoxins for proliferative disorders. Dr. Chandler received a B.S. in Chemistry from Stanford University, Palo Alto, CA, and a Ph.D. in Biochemistry from the University of Southern California with emphasis on the epigenetics of cancer.


INVESTOR RELATIONS CONTACT

Bonnie Ortega
Director of Investor Relations/Public Relations
12255 El Camino Real
Suite 250
San Diego, CA 92130
Phone: 858-436-1018
E-mail: [email protected]
Website: www.cardiumthx.com

Post a comment in the CXM blog

Cardium Therapeutics (CXM) Stock Quote and News:






Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated two thousand five hundred dollars by Cardium Therapeutics for its efforts in managing the dissemination of public corporate information on its website and to its database of subscribers and across select financial and social media websites. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/?page_id=190.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.